Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...

Goldman Sachs analyst Paul Choi downgraded the stock from "Neutral" to "Sell," setting a price target of $12, which is ...

Goldman Sachs cancelled a four-year-old policy to only take public companies that had two diverse board members, a ...

Goldman Sachs downgraded Dynavax (DVAX) to Sell from Neutral with a price target of $12, down from $15. The evolving competitive landscape in ...

Wall Street firms, including Goldman Sachs, Bank of America ... gets tens of thousands of applicants each year. For their 2024 programs, they got more than 315,000 applications to internships ...

Investment bank Goldman Sachs (GS) has named the companies it feels are most likely to be involved in a merger or acquisition (M&A) this ...

Goldman Sachs CEO David Solomon is scrapping a key ... But pressure from the new commander-in-chief has prompted a rethink. “As a result of legal developments related to board diversity ...

The Goldman Sachs Group downgraded shares of Informatica (NYSE:INFA – Free Report) from a buy rating to a neutral rating in a research note released on Friday morning, Marketbeat Ratings reports. A ...

The Pilbara Minerals Ltd (ASX: PLS) share price has lost a third of its value over the past 12 months. Is this a buying ...

From Westpac’s Anthony Miller to Commonwealth Bank’s Andrew Hinchliff, the Wall Street giant is well represented on ...